Sally C. Pipes

The Trump administration has released Medicare’s proposed physician payment rule for 2027. Buried in the hundreds of pages of technical regulations is a familiar outcome — another cut in what physicians will be paid to care for seniors. Under the proposal, Medicare’s basic payment rate would fall by as much as 1.7%. That may sound […]

American doctors already know how government payment works. Private insurers pay roughly twice what Medicare does. After inflation, Medicare physician payments have fallen 33% since 2001.

The next generation of medicines won't consist only of brand-new discoveries. It will also include better versions of the medicines patients already depend on.

But while excoriating insurance companies may be good politics, forcing everyone into a government insurance monopoly would be disastrous policy

As of May, the FDA had received 990 reports of adverse events associated with compounded versions of the GLP-1 semaglutide, the active ingredient in Wegovy and Ozempic.

Americans deserve medicines that are affordable. They also deserve medicines that are safe, FDA-approved, honestly marketed and developed in a system capable of producing tomorrow's cures.

More publicly financed insurance cards do not necessarily mean better access to care. They unquestionably mean more federal money for insurers.

While excoriating insurance companies may be good politics, forcing everyone into a government insurance monopoly would be disastrous policy.

Republicans have begun delivering that relief. Now they should make the contrast clear: Democrats want to send more taxpayer dollars to insurers. Republicans want to keep that money in patients' and employers' pockets.